37734-89-7

Basic information

• Product Name: 1-benzyl-2-phenyl-1H-imidazole
• Synonyms: 1-benzyl-2-phenyl-1H-imidazole;2-Phenyl-1-benzyl-1H-imidazole;1H-IMidazole,2-phenyl-1-(phenylMethyl)-;1B2PZ;Curezol 1B2PZ
• CAS NO: 37734-89-7
• Molecular Formula: C₁₆H₁₄N₂
• Molecular Weight: 234.29576
• EINECS: 253-646-2
• Mol File: 37734-89-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 427.9 °C at 760 mmHg
• Flash Point: 212.6 °C
• Appearance: /
• Density: 1.06 g/cm³
• Vapor Pressure: 1.59E-07mmHg at 25°C
• Refractive Index: 1.603
• PKA: 6.43±0.31(Predicted)
• CAS DataBase Reference: 1-benzyl-2-phenyl-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-2-phenyl-1H-imidazole(37734-89-7)
• EPA Substance Registry System: 1-benzyl-2-phenyl-1H-imidazole(37734-89-7)

Safety Data

• Hazardous Substances Data: 37734-89-7(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C16H14N2/c1-3-7-14(8-4-1)13-18-12-11-17-16(18)15-9-5-2-6-10-15/h1-12H,13H2

Upstream product

• 670-96-2 2-Phenylimidazole 
• 100-39-0 benzyl bromide 
• 4238-71-5 1-benzylimidazole 
• 6969-90-0 phenyl N,N-dimethylcarbamate 
• 108-90-7 chlorobenzene 
• 108-86-1 bromobenzene 

Downstream Products

• 670-96-2 2-Phenylimidazole 
• 1217902-36-7 5-(1-benzyl-2-phenyl-1H-imidazol-5-yl)-2-phenylpyrimidine 

Relevant articles and documents

Regioselective copper-diamine-catalyzed C-H arylation of 1,2,4-triazole ring with aryl bromides

A convenient methodology for the regioselective C-H arylation of 1,2,4-triazole ring was developed. Using a benchtop stable Cu-diamine catalyst system, C-H functionalization of a simple 1,2,4-triazole substrate with various aryl bromides was regioselectively accomplished at the C5 position of the triazole ring.

MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES

Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).